福莱特玻璃(06865.HK):新增发行不超7600万股H股申请获中国证监会核准
格隆汇6月11日丨福莱特玻璃(06865.HK)发布公告,近日,公司收到中国证监会《关于核准福莱特玻璃集团股份有限公司发行境外上市外资股的批复》(证监许可[2021]1949号)。中国证监会就公司新增发行H股申请,批复如下:
一.核准公司增发不超过7,600万股境外上巿外资股,每股面值人民币0.25元,全部为普通股。
二.本次发行完成后15个工作日内,公司应将本次发行的情况书面报告中国证监会。
三.证监批复自核准发行之日起12个月内有效。
四.公司在境外增发股票和上巿过程中,应严格遵守境内外有关法律、法规和规则。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.